First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Date of Release: June 23, 2022

Expiration Date: June 30, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description

During this webinar we will discuss two cases of composite lymphoma-the occurrence of both non-Hodgkin lymphoma (NHL) and classical Hodgkin lymphoma (cHL) in an individual patient. Composite is a relatively rare and poorly characterized phenomenon. We will describe the results of recent work in which we hypothesized that detailed analysis of the shared and divergent somatic mutations harbored by composite lymphoma patients might shed light on genetic drivers of composite lymphomagenesis. We performed exome sequencing of two cases of composite NHL and cHL and validated the somatic variants using an orthogonal sequencing approach. In, both cases we identified truncating mutations in TNFRSF14 that were shared between the cHL and NHL samples. Other shared somatic variants of potential significance included TP53, SRSF6, PLCG2, BCL10 and PCLO. Furthermore, sequencing of the B-cell receptor immunoglobulin heavy chain (IGH) gene region revealed clones with common V(D)J gene usage in the NHL and cHL cases. These case studies suggest a common lymphoma precursor in both cases of composite lymphoma. The shared somatic variants we identified may represent early events in lymphomagenesis and potential therapeutic targets.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Describe the usage exome sequencing to identify somatic variation within the lymphoma genomes from patient samples
2. Describe the use V(D)J gene usage to identify the clonal origin of B-cell lymphomas
3. Evaluate the potential for shared common origin of unique lymphomas in a single patient based on sequencing data

Moderator:

Beth Pitel, MS

Senior Developer, Assistant Professor in the Division of Laboratory Genetics and Genomics, Office of Translational Research, Innovation, and Test Development, Mayo Clinic, Rochester, MN

Presenter(s):

Felicia Gomez, PhD

Washington University in St. Louis (WU)

Dr. Gomez is an Instructor in the Griffith and Fehniger Laboratories at the McDonnell Genome Institute and The Department of Medicine - Division of Oncology at Washington University School of Medicine. Dr. Gomez is leading a deep sequencing analysis of Hodgkin lymphoma genomes with the goal of describing somatic events characteristic of this malignancy. Dr. Gomez collaborates with members of the Griffith and Fehniger laboratories on projects related to the genomics of Hodgkin and Non-Hodgkin lymphomas. Dr. Gomez’s research goals include developing strategies to translate genomic data into improved patient care. She is specifically interested in working toward the inclusion of diverse human populations in translational genomic research.

Lauren Shea, MD, MS

The University of Alabama at Birmingham

Dr. Shea is an Associate Scientist at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham and an Associate Professor of Medicine with an emphasis in Hematology and Oncology. She completed a Master of Science degree in immunology as well as doctorate and postdoctoral fellowship at Washington University in St. Louis, MO and completed residency at the University of Alabama at Birmingham. Dr. Shea has a particular interest in lymphoma, including both B-cell and T-cell lymphomas. She is involved in developing novel immune-based therapies to help lymphoma patients achieve durable remissions with decreased toxicity.

Planning Committee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP 

Accredited Continuing Education Information:

Continuing Medical Education (CME AMA & CME Other)

Accreditation

Credit DesignatioThe American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.n

The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.